Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177971 | 0.90 | PRMT5 (0.39) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL4185266 | 0.88 | KDM4E (0.41) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL4183203 | 0.88 | FGFR1 (0.41) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL4189829 | 0.86 | FGFR3 (0.39) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL4182669 | 0.84 | PGK1 (0.51) | MAPK1PGK1PIK3CAPIK3CDPIK3CG | |
| SCHEMBL13929793 | 0.82 | PLAU (0.45) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL4177980 | 0.81 | S1PR1 (0.48) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL4191726 | 0.78 | PRMT5 (0.39) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL4182844 | 0.75 | KDM4E (0.43) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL4186911 | 0.74 | ROCK2 (0.39) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | IDENIX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009014730-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | SERPINB1, SPINT2, PRSS1 | FGFR1 4085/4885FGFR2 4528/4885FGFR3 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.